论文部分内容阅读
目的:使用声脉冲辐射力成像技术(ARFI),评价在恩替卡韦分散片抗病毒的基础上联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的疗效。方法:对96例慢性乙型肝炎患者经恩替卡韦分散片联合复方鳖甲软肝片治疗前后行声脉冲辐射力成像检查,记录所检测到的VTQ值,并同时检测肝功能、肝纤维化指标等,观察时间节点为24和48周,分析VTQ值、肝功能、肝纤维化指标的变化。计量资料用(x珋±s)表示,采用t检验,P<0.05为差异有统计学意义。结果 96例患者在治疗24周及48周,患者的VTQ值、常规检查的肝功能指标(ALT、AST)和肝纤维化指标(HA、LN、CIV和PCⅢ)均较治疗前明显降低(P<0.05);且治疗48周后的VTQ值、肝纤维化指标也分别显著低于治疗24周后的值(P<0.05),然而,48周后肝功能指标相对24周的值没有统计学意义(P>0.05)。结论与传统肝纤维化指标相比,声脉冲辐射力成像是一种简便可靠的临床检查肝纤维化及评价疗效的技术手段。同时,该临床研究也表明:恩替卡韦分散片联合复方鳖甲软肝片是治疗慢性乙型肝炎肝纤维化的有效组合。
OBJECTIVE: To evaluate the therapeutic effect of Fufang Biejia Ruangan Tablet on chronic hepatitis B liver fibrosis based on entecavir dispersible tablet anti-virus using acoustic pulse radiation imaging (ARFI) technique. Methods: 96 patients with chronic hepatitis B were treated with entecavir dispersible tablets and Fufang Biejia Ruangan Tablet before and after radiofrequency imaging, and the detected VTQ values were recorded. At the same time, the indexes of liver function and liver fibrosis , The time points of observation were 24 and 48 weeks, and the changes of VTQ value, liver function and liver fibrosis index were analyzed. Measurement data (x 珋 ± s), using t test, P <0.05 was considered statistically significant. Results The 96 patients had significantly lower VTQ values, ALT and AST, and liver fibrosis indexes (HA, LN, CIV and PCⅢ) at 24 weeks and 48 weeks after treatment (P <0.05). After 48 weeks of treatment, the VTQ value and the index of liver fibrosis were also significantly lower than those of the 24th week after treatment (P <0.05). However, there was no statistical difference between the 48th week and the 24th week Significance (P> 0.05). Conclusion Compared with the traditional indicators of liver fibrosis, acoustic pulse radiation imaging is a simple and reliable method for clinical examination of liver fibrosis and evaluation of curative effect. At the same time, the clinical study also shows: Entecavir dispersible tablets combined with Fufang Biejia Ruangan Tablet is an effective combination for the treatment of chronic hepatitis B liver fibrosis.